Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders

Jaswinder K. Ghuman, Michael G. Aman, Luc Lecavalier, Mark A. Riddle, Alan Gelenberg, Ron Wright, Sydney A Rice, Harinder S. Ghuman, Carolyn Fort

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective: The aim of this study was to investigate the short-term efficacy and safety of methylphenidate (MPH) to treat attention-deficit/hyperactivity disorder (ADHD) symptoms in an understudied population of preschoolers with pervasive developmental disorder (PDD) or intellectual disability (ID). Methods: Fourteen preschoolers with developmental disorders (DD, n = 14; PDD, n = 12; ID, n = 2) underwent MPH titration in a single-blind manner followed by a 4-week double-blind crossover phase. Each child was administered placebo for 2 weeks and "optimal dose" for 2 weeks. The primary outcome measure was the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ADHD subscale of the Conners' Parent Rating Scale-Revised (CPRS-R-DSM-IV-ADHD). Results: MPH improved parent-rated ADHD symptoms of the preschoolers; 50% were rated as responders. The CPRS-R-DSM-IV-ADHD subscale was significant for the PDD subgroup (p = 0.005, Cohen d = 0.97) and marginally significant for the entire DD sample (p = 0.08, Cohen d = 0.50). Half of the preschoolers experienced side effects with MPH, including reports of increased stereotypic behavior, upset stomach, sleep-related difficulties, and emotional lability. One child discontinued during titration due to side effects. Conclusion: The predominant direction of response in these preschoolers with both ADHD and PDD/ID favored MPH, even though the response was more subtle and variable than in older and typically developing children. Due to high rates of adverse effects, preschoolers should be monitored closely.

Original languageEnglish (US)
Pages (from-to)329-339
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume19
Issue number4
DOIs
StatePublished - Aug 1 2009

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Cross-Over Studies
Placebos
Diagnostic and Statistical Manual of Mental Disorders
Intellectual Disability
Developmental Disabilities
Stomach
Sleep
Outcome Assessment (Health Care)
Safety
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. / Ghuman, Jaswinder K.; Aman, Michael G.; Lecavalier, Luc; Riddle, Mark A.; Gelenberg, Alan; Wright, Ron; Rice, Sydney A; Ghuman, Harinder S.; Fort, Carolyn.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 19, No. 4, 01.08.2009, p. 329-339.

Research output: Contribution to journalArticle

Ghuman, Jaswinder K. ; Aman, Michael G. ; Lecavalier, Luc ; Riddle, Mark A. ; Gelenberg, Alan ; Wright, Ron ; Rice, Sydney A ; Ghuman, Harinder S. ; Fort, Carolyn. / Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. In: Journal of Child and Adolescent Psychopharmacology. 2009 ; Vol. 19, No. 4. pp. 329-339.
@article{c8d6a74fb4b645aeb8fd52fd0db083ef,
title = "Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders",
abstract = "Objective: The aim of this study was to investigate the short-term efficacy and safety of methylphenidate (MPH) to treat attention-deficit/hyperactivity disorder (ADHD) symptoms in an understudied population of preschoolers with pervasive developmental disorder (PDD) or intellectual disability (ID). Methods: Fourteen preschoolers with developmental disorders (DD, n = 14; PDD, n = 12; ID, n = 2) underwent MPH titration in a single-blind manner followed by a 4-week double-blind crossover phase. Each child was administered placebo for 2 weeks and {"}optimal dose{"} for 2 weeks. The primary outcome measure was the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ADHD subscale of the Conners' Parent Rating Scale-Revised (CPRS-R-DSM-IV-ADHD). Results: MPH improved parent-rated ADHD symptoms of the preschoolers; 50{\%} were rated as responders. The CPRS-R-DSM-IV-ADHD subscale was significant for the PDD subgroup (p = 0.005, Cohen d = 0.97) and marginally significant for the entire DD sample (p = 0.08, Cohen d = 0.50). Half of the preschoolers experienced side effects with MPH, including reports of increased stereotypic behavior, upset stomach, sleep-related difficulties, and emotional lability. One child discontinued during titration due to side effects. Conclusion: The predominant direction of response in these preschoolers with both ADHD and PDD/ID favored MPH, even though the response was more subtle and variable than in older and typically developing children. Due to high rates of adverse effects, preschoolers should be monitored closely.",
author = "Ghuman, {Jaswinder K.} and Aman, {Michael G.} and Luc Lecavalier and Riddle, {Mark A.} and Alan Gelenberg and Ron Wright and Rice, {Sydney A} and Ghuman, {Harinder S.} and Carolyn Fort",
year = "2009",
month = "8",
day = "1",
doi = "10.1089/cap.2008.0137",
language = "English (US)",
volume = "19",
pages = "329--339",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders

AU - Ghuman, Jaswinder K.

AU - Aman, Michael G.

AU - Lecavalier, Luc

AU - Riddle, Mark A.

AU - Gelenberg, Alan

AU - Wright, Ron

AU - Rice, Sydney A

AU - Ghuman, Harinder S.

AU - Fort, Carolyn

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Objective: The aim of this study was to investigate the short-term efficacy and safety of methylphenidate (MPH) to treat attention-deficit/hyperactivity disorder (ADHD) symptoms in an understudied population of preschoolers with pervasive developmental disorder (PDD) or intellectual disability (ID). Methods: Fourteen preschoolers with developmental disorders (DD, n = 14; PDD, n = 12; ID, n = 2) underwent MPH titration in a single-blind manner followed by a 4-week double-blind crossover phase. Each child was administered placebo for 2 weeks and "optimal dose" for 2 weeks. The primary outcome measure was the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ADHD subscale of the Conners' Parent Rating Scale-Revised (CPRS-R-DSM-IV-ADHD). Results: MPH improved parent-rated ADHD symptoms of the preschoolers; 50% were rated as responders. The CPRS-R-DSM-IV-ADHD subscale was significant for the PDD subgroup (p = 0.005, Cohen d = 0.97) and marginally significant for the entire DD sample (p = 0.08, Cohen d = 0.50). Half of the preschoolers experienced side effects with MPH, including reports of increased stereotypic behavior, upset stomach, sleep-related difficulties, and emotional lability. One child discontinued during titration due to side effects. Conclusion: The predominant direction of response in these preschoolers with both ADHD and PDD/ID favored MPH, even though the response was more subtle and variable than in older and typically developing children. Due to high rates of adverse effects, preschoolers should be monitored closely.

AB - Objective: The aim of this study was to investigate the short-term efficacy and safety of methylphenidate (MPH) to treat attention-deficit/hyperactivity disorder (ADHD) symptoms in an understudied population of preschoolers with pervasive developmental disorder (PDD) or intellectual disability (ID). Methods: Fourteen preschoolers with developmental disorders (DD, n = 14; PDD, n = 12; ID, n = 2) underwent MPH titration in a single-blind manner followed by a 4-week double-blind crossover phase. Each child was administered placebo for 2 weeks and "optimal dose" for 2 weeks. The primary outcome measure was the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ADHD subscale of the Conners' Parent Rating Scale-Revised (CPRS-R-DSM-IV-ADHD). Results: MPH improved parent-rated ADHD symptoms of the preschoolers; 50% were rated as responders. The CPRS-R-DSM-IV-ADHD subscale was significant for the PDD subgroup (p = 0.005, Cohen d = 0.97) and marginally significant for the entire DD sample (p = 0.08, Cohen d = 0.50). Half of the preschoolers experienced side effects with MPH, including reports of increased stereotypic behavior, upset stomach, sleep-related difficulties, and emotional lability. One child discontinued during titration due to side effects. Conclusion: The predominant direction of response in these preschoolers with both ADHD and PDD/ID favored MPH, even though the response was more subtle and variable than in older and typically developing children. Due to high rates of adverse effects, preschoolers should be monitored closely.

UR - http://www.scopus.com/inward/record.url?scp=69549087898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549087898&partnerID=8YFLogxK

U2 - 10.1089/cap.2008.0137

DO - 10.1089/cap.2008.0137

M3 - Article

VL - 19

SP - 329

EP - 339

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -